Nothing Special   »   [go: up one dir, main page]

MX2022014150A - Composiciones para aumentar la semivida de un agente terapeutico en caninos y metodos de uso. - Google Patents

Composiciones para aumentar la semivida de un agente terapeutico en caninos y metodos de uso.

Info

Publication number
MX2022014150A
MX2022014150A MX2022014150A MX2022014150A MX2022014150A MX 2022014150 A MX2022014150 A MX 2022014150A MX 2022014150 A MX2022014150 A MX 2022014150A MX 2022014150 A MX2022014150 A MX 2022014150A MX 2022014150 A MX2022014150 A MX 2022014150A
Authority
MX
Mexico
Prior art keywords
compositions
life
methods
canines
therapeutic agent
Prior art date
Application number
MX2022014150A
Other languages
English (en)
Inventor
William Brondyk
Brett Chevalier
Juergen Horn
Madhusudan Natarajan
Original Assignee
Invetx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invetx Inc filed Critical Invetx Inc
Publication of MX2022014150A publication Critical patent/MX2022014150A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan composiciones para aumentar la semivida de un polipéptido o polipéptidos en un canino y métodos de uso. Las composiciones implican regiones Fc de IgG canina variantes.
MX2022014150A 2020-05-11 2021-05-11 Composiciones para aumentar la semivida de un agente terapeutico en caninos y metodos de uso. MX2022014150A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023083P 2020-05-11 2020-05-11
US202063122417P 2020-12-07 2020-12-07
PCT/US2021/031826 WO2021231464A1 (en) 2020-05-11 2021-05-11 Compositions for increasing half-life of a therapeutic agent in canines and methods of use

Publications (1)

Publication Number Publication Date
MX2022014150A true MX2022014150A (es) 2023-02-27

Family

ID=76375622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014150A MX2022014150A (es) 2020-05-11 2021-05-11 Composiciones para aumentar la semivida de un agente terapeutico en caninos y metodos de uso.

Country Status (10)

Country Link
US (3) US11434276B2 (es)
EP (1) EP4149969A1 (es)
JP (1) JP2023526225A (es)
KR (1) KR20230034954A (es)
CN (1) CN115867572A (es)
AU (1) AU2021270564A1 (es)
BR (1) BR112022022922A2 (es)
CA (1) CA3178123A1 (es)
MX (1) MX2022014150A (es)
WO (1) WO2021231464A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54657A (fr) 2019-01-03 2021-11-10 Invetx Inc Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation
US11498953B2 (en) 2020-07-10 2022-11-15 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
MX2024002150A (es) 2021-08-20 2024-03-08 Intervet Int Bv Anticuerpos y proteinas de fusion de igg con una semivida prolongada.
WO2024145278A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024155982A2 (en) 2023-01-20 2024-07-25 Invetx, Inc. Bispecific binding agents for use in companion animals
WO2024165857A1 (en) * 2023-02-08 2024-08-15 Levicept Limited Fusion protein

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
JP3126980B2 (ja) 1991-03-11 2001-01-22 ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド レニラ（ｒｅｎｉｌｌａ）ルシフェラーゼのクローニング及び発現
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
US6232107B1 (en) 1998-03-27 2001-05-15 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2411050A4 (en) * 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20200181258A1 (en) * 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
MX2020001707A (es) 2017-08-15 2020-03-20 Kindred Biosciences Inc Variantes igg fc para uso veterinario.
JP7399880B2 (ja) * 2018-01-26 2023-12-18 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
CN111819197A (zh) 2018-03-12 2020-10-23 硕腾服务有限责任公司 抗ngf抗体及其方法
EP3849610A4 (en) 2018-09-14 2022-12-07 Kindred Biosciences, Inc. ANTI-IL4 RECEPTOR ANTIBODIES FOR VETERINARY USE
MX2021004313A (es) 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
WO2020139984A1 (en) 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use
MA54657A (fr) 2019-01-03 2021-11-10 Invetx Inc Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation
EP4107179A1 (en) 2020-02-19 2022-12-28 adivo GmbH Modified fc regions
EP4136106A1 (en) 2020-04-17 2023-02-22 Zoetis Services LLC Canine antibody variants
KR20230005158A (ko) 2020-04-17 2023-01-09 조에티스 서비시즈 엘엘씨 고양잇과 항체 변이체
US11498953B2 (en) 2020-07-10 2022-11-15 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use

Also Published As

Publication number Publication date
WO2021231464A1 (en) 2021-11-18
AU2021270564A1 (en) 2023-02-02
US20230127241A1 (en) 2023-04-27
US20240327497A1 (en) 2024-10-03
KR20230034954A (ko) 2023-03-10
CN115867572A (zh) 2023-03-28
CA3178123A1 (en) 2021-11-18
US20210347854A1 (en) 2021-11-11
BR112022022922A2 (pt) 2023-01-17
JP2023526225A (ja) 2023-06-21
EP4149969A1 (en) 2023-03-22
US11434276B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2021008144A (es) Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
MX2022014150A (es) Composiciones para aumentar la semivida de un agente terapeutico en caninos y metodos de uso.
MX2023000500A (es) Composiciones para aumentar la semivida de un agente terapeutico en felinos y modos de uso.
MX2020010912A (es) Proteínas il-15/il-15ra de fusión a fc heterodiméricas y usos de las mismas.
SA519401646B1 (ar) الجلوبولينات المناعية واستخداماتها
ZA202100390B (en) Fusion constructs and methods of using thereof
EA201891656A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний
MX2023006639A (es) Composiciones para aumentar la semivida de un agente terapeutico en ganado y metodos de uso.
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
MX2020014296A (es) Variantes de interleucina-2 y sus métodos de uso.
SA521422459B1 (ar) مثبطات غير قابلة للانعكاس لتفاعل المينين - mll
MX2019014023A (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
MX2021003765A (es) Proteínas il-12 de fusión a fc heterodimérico.
MA40094A1 (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MX2020008333A (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
BR112021021843A8 (pt) Composições de proteínas de fusão quiméricas modificadas e método de uso das mesmas
PE20140303A1 (es) Polipeptidos interleuquina-2 mutantes
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
EA202192555A1 (ru) Комбинированная терапия для лечения рака
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
MX2022003306A (es) Inmunocitoquina que comprende un complejo de proteina heterodimerico basado en il-15/il-15ra y su uso.
GB202006974D0 (en) Chimaeric proteins and therapeutic agents
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
MX2023012131A (es) Construcciones de il-2.
PH12020552270A1 (en) Anti-steap1 antigen-binding protein